Fatty liver disease (MASLD/MASH) trials in Austria

In Austria 9 Also abroad 367

9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseNot yet taking people in Austria
Personalized Dietary Feedback to Reduce Hepatic Steatosis in Patients With MASLD
Where
Vienna
Age
18 years to 80 years
People
174
Run by
Medical University of Vienna
See details and how to joinNCT07914829
Phase 3Taking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
Graz, Linz, Vienna, Wels
Age
18 years and over
People
1,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
Phase 3Taking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
Graz, Linz, Vienna, Wels
Age
18 years and over
People
1,590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Graz, Innsbruck, Klagenfurt Am Woerthersee, St. Poelten, Wels
Age
18 years to 80 years
People
1,350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
Phase 3Not yet taking people in Austria
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
Where
Graz, Klagenfurt Am Woerthersee, Vienna
Age
18 years and over
People
382 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 · EU 2026-525755-82-00
Phase 3Not yet taking people in Austria
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
Where
Graz, Klagenfurt Am Woerthersee, Vienna
Age
18 years and over
People
69 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 · EU 2026-525757-37-00
Phase 3Taking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
Graz, Salzburg, Vienna, Wiener Neustadt
Age
18 years and over
People
4,500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
Phase 3Taking people
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Where
Graz, Innsbruck, Klagenfurt Am Woerthersee, Vienna
Age
18 years to 75 years
People
1,250 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00
No phaseTaking people
Cold-induced Brown Fat Activation and Hepatic Steatosis
Where
Vienna
Age
18 years to 50 years
People
26
Run by
Medical University of Vienna
See details and how to joinNCT03811236